

CITATION REPORT

List of articles citing

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

DOI: 10.3201/eid2505.181823

Emerging Infectious Diseases, 2019, 25, 936-943.

Source: <https://exaly.com/paper-pdf/73278223/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
54	Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening. <i>Journal of Antibiotics</i> , 2019 , 72, 719-728	3.7	26
53	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	64
52	Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2336-2344	11.6	11
51	Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies. <i>Pharmaceutics</i> , 2019 , 11,	6.4	8
50	A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	2
49	Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective. <i>Future Microbiology</i> , 2020 , 15, 779-799	2.9	5
48	ERS International Congress, Madrid, 2019: highlights from the Respiratory Infections Assembly. <i>ERJ Open Research</i> , 2020 , 6,	3.5	1
47	Breastfeeding in women living with tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020 , 24, 880-891	2.1	3
46	Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients. <i>International Journal of Infectious Diseases</i> , 2020 , 100, 196-198	10.5	1
45	The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis. <i>FEMS Microbiology Reviews</i> , 2021 , 45,	15.1	4
44	Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment. <i>EBioMedicine</i> , 2020 , 55, 102747	8.8	16
43	Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. <i>New England Journal of Medicine</i> , 2020 , 382, 893-902	59.2	207
42	New perspectives on difficult-to-treat tuberculosis based on old therapeutic approaches. <i>International Journal of Infectious Diseases</i> , 2020 , 92S, S91-S99	10.5	1
41	Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 111-119	10.2	13
40	The effects of MDR/RR-TB treatment on HIV disease: A systematic review of literature. <i>PLoS ONE</i> , 2021 , 16, e0248174	3.7	1
39	Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety. <i>Infectious Diseases of Poverty</i> , 2021 , 10, 32	10.4	3
38	Antitubercular Agents. 1-110		

37	Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1362-1369	11.6	3
36	Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid. <i>Microorganisms</i> , 2021 , 9,	4.9	3
35	A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 897-910	2.2	1
34	Cost-Effectiveness of Bedaquiline in Multidrug Resistant Tuberculosis: A Review. <i>Open Public Health Journal</i> , 2021 , 14, 282-290	0.6	
33	Novel treatments in multidrug-resistant tuberculosis. <i>Current Opinion in Pharmacology</i> , 2021 , 59, 103-115	5.1	0
32	Emergence of bedaquiline-resistance in a high-burden country of tuberculosis. <i>European Respiratory Journal</i> , 2021 ,	13.6	2
31	Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis. <i>International Journal of Infectious Diseases</i> , 2021 , 110, 179-186	10.5	2
30	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. <i>Pulmonology</i> , 2021 , 27, 403-412	3.7	5
29	Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 457-470	6.2	2
28	Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3563-e3571	11.6	7
27	The multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis. <i>Tuberculosis and Lung Diseases</i> , 2020 , 98, 56-62	0.6	13
26	Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019. <i>Tuberculosis and Lung Diseases</i> , 2020 , 98, 5-15	0.6	9
25	Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021 , 10, 457-467	4.8	0
24	Antituberculosis and antileprosy medications. <i>Side Effects of Drugs Annual</i> , 2020 , 299-308	0.2	1
23	Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment.		
22	Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. <i>Frontiers in Microbiology</i> , 2021 , 12, 754249	5.7	2
21	Bedaquiline for multidrug-resistant TB in paediatric patients. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021 , 25, 716-724	2.1	0
20	Bedaquiline for multidrug-resistant TB in paediatric patients. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021 , 25, 716-724	2.1	1

19	Optimized loading dose strategies for bedaquiline when restarting interrupted drug-resistant tuberculosis treatment.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , AAC0174921	5.9	
18	Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort.. <i>Clinical Infectious Diseases</i> , 2022 ,	11.6	1
17	Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan.. <i>BMC Microbiology</i> , 2022 , 22, 62	4.5	1
16	Effectiveness of chemotherapy of multidrug-resistant tuberculosis using bedaquiline. <i>Pulmonologiya</i> , 2022 , 32, 103-108	0.8	
15	Interim Outcomes and Adverse Events among Drug-Resistant Tuberculosis Patients Treated with Bedaquiline in the Philippines. <i>Journal of Tuberculosis Research</i> , 2022 , 10, 61-74	0.2	0
14	Bedaquiline in drug-resistant tuberculosis: A mini-review. <i>Current Molecular Pharmacology</i> , 2022 , 15,	3.7	
13	Assessment of Adverse Drug Events, Their Risk Factors, and Management Among Patients Treated for Multidrug-Resistant TB: A Prospective Cohort Study From Pakistan. <i>Frontiers in Pharmacology</i> , 2022 , 13,	5.6	0
12	Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. <i>Jornal Brasileiro De Pneumologia</i> , e20210384	1.1	2
11	Utilization of Bedaquiline among Drug Resistant-Tuberculosis patients. <i>Asian Journal of Pharmaceutical Research</i> , 2022 , 132-136	2.1	
10	Evolution of Machine Learning in Tuberculosis Diagnosis: A Review of Deep Learning-Based Medical Applications. 2022 , 11, 2634		4
9	Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China. 2022 , 22,		0
8	The Characteristics and Patterns of Drug-Resistant Pulmonary Tuberculosis in Eastern India. 2022 , 7, 244		0
7	Rifampicin resistance and mortality in patients hospitalised with HIV-associated tuberculosis. 2022 , 23,		0
6	Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis.		0
5	Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation. 2022 , 11, 1622		0
4	The Introduction of Bedaquiline Regimen for Drug-Resistant Tuberculosis in the Philippines: An Operational Study. 2022 , 10, 205-219		0
3	Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. 2022 , 22,		1
2	The role of alternative regimens in the management of tuberculosis in transplant recipients: From past challenges to future opportunities. 2022 , 24,		0

- ¹ A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea. **2023**, 23,

O